Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Lilly del Caribe, Inc. (PR05)
WARNING LETTER
•Lilly del Caribe, Inc. (PR05)•July 31, 2009

Lilly del Caribe, Inc. (PR05) – FDA Warning Letter, Jul 31, 2009

Record Details

This Warning Letter, dated [Date of Letter], addresses Eli Lilly & Company's active pharmaceutical ingredient (API) manufacturing facility, Lilly del Caribe, following a July 08-31, 2009 inspection. The inspection revealed a significant deviation from Current Good Manufacturing Practice (CGMP) requirements for API manufacture, rendering their Lyspro Insulin Zinc Crystals API adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

The primary violation identified was the firm's failure to adequately investigate critical deviations or batch failures. Specifically, investigation TR# (b)(4) determined the disposition of 36 API batches based on an unvalidated test method. This investigation concerned 36 batches of (b)(4) exhibiting (b)(4), a process affecting the API. The investigation found an increase in (b)(4) which can cause (b)(4) affecting API quality. Twenty-four of these batches were released based on results from the unvalidated (b)(4) test, despite knowledge of a similar event at a sister plant. The (b)(4) test, intended as a limit test, was improperly used for final disposition. Subsequent studies in April 2008 showed the (b)(4) test method was not linear, indicating no assurance of the actual percentage of (b)(4) present in affected batches. The firm failed to assess all affected batches released for

Company
Lilly del Caribe, Inc. (PR05)
Inspection date
July 31, 2009
Product type
Drugs
Office
San Juan District Office
People
  • Sandra I. Galindez Feliciano
  • Maridalia Torres-Irizarry ( District Director )
View Company Profile

ID · 73ce82e4-13c3-4bb8-8dd9-3c1280ffcfa8

Violation Codes2
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Lilly del Caribe, Inc. (PR05)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.